TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05597163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low concentration atropine (0.01%)
Description: 0.01% atropine eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low concentration atropine (0.025%)
Description: 0.025% atropine eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low concentration atropine (0.05%)
Description: 0.05% atropine eye drop

Intervention type: DRUG
Group type: OTHER
Intervention: low concentration atropine (0.05%)
Description: 0.05% atropine eye drop

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo eye drop
Study: NCT05928273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corheart 6 Left Ventricular Assist System
Description: Implantation of left ventricular assist device for hemodynamic support
Study: NCT05695079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No cooling (control)
Description: Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric fan (low airflow)
Description: Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
Study: NCT06436976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-002 (Lactobacillus reuteri ATG-F4
Description: The group that will be consuming probiotics for 12 weeks.
Study: NCT04907097

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Monomeric and oligomeric flavanols
Description: Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Monomeric and oligomeric flavanols
Description: Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo capsuled will be used as a comparator.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo capsuled will be used as a comparator.
Study: NCT05461092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tampa Scale of Kinesiophobia
Description: Questionnaire assessing Kinesiophobia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Recovery 15
Description: Questionnaire assessing postoperative quality of recovery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Recovery 15
Description: Questionnaire assessing postoperative quality of recovery
Study: NCT05469737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oral Azacitidine
Description: Specified dose on specified days
Study: NCT05913752

Intervention type: DRUG
Group type: OTHER
Intervention: CMND-100
Description: The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CMND-100
Description: The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class

Intervention type: DRUG
Group type: OTHER
Intervention: CMND-100
Description: The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class

Intervention type: DRUG
Group type: OTHER
Intervention: CMND-100
Description: The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class
Study: NCT05632861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuHuangLianzonggan capsule
Description: HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HuHuangLianzonggan capsule placebo
Description: HuHuangLianzonggan capsule placebo, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
Study: NCT00987818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin measurement
Description: Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Procalcitonin measurement
Description: Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
Study: NCT05618704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein infant formula
Description: The subjects will take the formula for 16 weeks
Study: NCT05392842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corchorus Olitorius Buccal fast dissolving Films
Description: Corchorus Olitorius Buccal fast dissolving Films

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plain mucoadhesive fast dissolving film
Description: plain mucoadhesive fast dissolving film
Study: NCT06545539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Preparedness Exercise Class
Description: The class will be held bi-weekly at two different locations. To ensure consistency across groups, the instructor(s) will adhere to a standardized class outline. Exercise modifications will be provided as necessary to adjust the intensity, ensuring all participants can follow the program.
Study: NCT05730933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Subjects will receive a behavioral intervention with additional education in combination with more frequent follow up and patient reminders
Study: NCT06456775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-SSM
Description: Tele-SSM an individual-level psychosocial intervention based on cognitive behavior therapy principles and non-violent communication. The intervention consists of the following 10 sessions delivered through 10 weekly coaching calls delivered by Zoom (audio only).
Study: NCT05006287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs)
Description: NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin Group (Comparator):~Patients randomized to the warfarin group will receive warfarin titrated to achieve a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0). Warfarin will be started as early as post-operative day 1 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until INR is 2.0 or above.
Study: NCT04797104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: 300 mg Q4W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lerodalcibep
Description: 300 mg Q4W
Study: NCT05211570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB8939
Description: Intravenous injection (from an initial dose of 0.9 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB8939
Description: Intravenous injection (from an initial dose of 0.9 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous injection (75 mg/m²)
Study: NCT04968730

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative rehabilitation nursing
Description: Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation nursing
Description: Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B
Study: NCT04930289

Intervention type: DEVICE
Intervention: LungGuard
Description: The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours.

Intervention type: DEVICE
Intervention: BAROGuard
Description: The BAROguard (the System) is ultraportable hypothermic preservation and transport system intended for use with donor lungs. BAROguard is a legally marketed, FDA cleared medical device in the United States. The intended organ storage time for BAROguard™ is up to 8 hours.
Study: NCT05695079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric fan (high airflow)
Description: Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
Study: NCT05182684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Patch(TriBell Lab)
Description: Electrocardiograms were recorded using VP-100 for more than six hours and transmitted to a central data server located in Seoul National University Hospital.~The data on a central server was confirmed and evaluated.
Study: NCT05521087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75276617
Description: JNJ-75276617 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75276617
Description: JNJ-75276617 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
Study: NCT05885425

Intervention type: BEHAVIORAL
Intervention: Telemedicine correction of medical treatment
Description: On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine

Intervention type: BEHAVIORAL
Intervention: Education for proper lifestyle
Description: Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
Study: NCT06353373

Intervention type: OTHER
Intervention: Application of the modified DeVTEcare system
Description: The modified DeVTEcare system, which incorporates bundled guideline-based VTE prevention measures, will be utilized to assist healthcare providers in VTE prophylaxis after September 2024.
Study: NCT06121323

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lactate infusion
Description: Dosage of sodium-lactate: 0.5 mol/L; 3 mL/kg/time; maximal 300 mL/hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lactate ingestion
Description: Oral dose is equal to the i.v. dose.
Study: NCT05629858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-h Time restricted eating (TRE)
Description: Ad libitum food intake from 1-7 pm every day Fasting from 7-1 pm every day (18-h fast)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Description: 25% energy restriction every day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual diet
Study: NCT05975593

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor collection via biopsy
Description: Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence.
Study: NCT05370040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC2 Vaccine
Description: AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC2 Vaccine
Description: AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC2 Vaccine
Description: AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC2 Vaccine
Description: AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC3 Vaccine
Description: AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC3 Vaccine
Description: AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC3 Vaccine
Description: AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC3 Vaccine
Description: AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC3 Vaccine
Description: AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: EUA or approved vaccine
Description: Janssen or Pfizer vaccines (control arm)
Study: NCT06070467

Intervention type: OTHER
Intervention: Mixed Methods Research (MMR) using quantitative (QUAN) and qualitative (QUAL) tools
Description: A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).~The QUAN study is a cross-sectional study including short-term re-test repetition (children/teenagers only) using the following PROMs for children/teenagers:~1. Self-reported questionnaires for patients (FVQ-CYP and VQoL-CYP)~2. For caregivers: PEM-CY questionnaires~The QUAL study will rely on the following instruments:~1. Semi-directive interviews,~2. Focus groups,~3. Field observation.
Study: NCT05543616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Description: Injection in the muscle
Study: NCT05543616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle
Study: NCT05521087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine chemotherapy will be administered as IV infusion for participants with AML.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine chemotherapy will be administered as IV infusion for participants with AML.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Chemotherapy
Description: Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Chemotherapy
Description: Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.